Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

NCT04938297 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER_GOV

Sponsor class

Conditions

Central Nervous System Lymphoma

Interventions

DRUG: Rituximab, Lenalidomide, Zanubrutinib
DRUG: Lenalidomide, Zanubrutinib
DRUG: Lenalidomide

Sponsor

Henan Cancer Hospital